Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2003

View Archived Issues

Antitumor effects of ZD-6126 due to changes in endothelial cell morphology

Euglucon and Lanirapid rights to be transferred to Chugai

Cardiovascular benefits found for transdermal vs. oral estrogen in postmenopausal women

Bacterial resistance and oropharyngeal colonization after long-term antibiotic therapy for acne

Effective use of subantimicrobial doses of doxycycline in moderate facial acne

Topical testosterone improves erectile response in male hypogonadism unresponsive to sildenafil

Safety and efficacy of lofexidine in children with ADHD and tics

New NOS inhibitors and their use in arthritis, pain and migraine reported by AstraZeneca

Kaken presents new VLA-4/LPAM-1 antagonists

Thiazolidine DPP-IV inhibitors described by Mitsubishi Pharma

Novel beta-secretase inhibitors in early development at Elan

Novel adenosine A2A receptor antagonists and their use in Parkinson's disease

Suntory patent covers preparation and use of novel NF-kB activation inhibitors

Kowa researchers prepare and test orally available IL-1beta production inhibitors

Amylin fragments reported to stimulate bone growth

New FTase inhibitors in Wyeth development pipeline

Antisoma's anticancer drug AS-1406 shows promise in preclinical trials

FDA approves first treatment for Fabry's disease

ISV-403 moves into phase I clinical trials

Locus and Speedel collaborate to design novel renin inhibitors

Enrollment completed in phase IIa Onyvax-P trial

Allergan and Acadia announce new drug discovery and development collaboration

FDA approves Aldurazyme for MPS I

Full inverse agonist at an HCMV-encoded G-protein-coupled receptor identified

Approval and/or launch of major ophthalmic products reported by Allergan

Phase II trials of human GLP-1 analogue completed at Novo Nordisk

Neurocrine Biosciences acquires compound for ED divested by Pharmacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
An early stage 85% remissions rate in AML drives Aptevo’s stock surge
BioWorld
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
BIO 2025: Makary lays out FDA’s path, launches pilot review program
BioWorld
On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
Alphadesign: AI creating proteins from scratch
BioWorld Science
The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...